Active Music-Based Intervention in Patients With Chronic Low Back Pain
NCT06940063, Not applicable, Recruiting, Sharon Wang-Price
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Active Music-Based Intervention in Patients With Chronic Low Back Pain | ClinicalTrials.gov |
| NCT number | NCT06940063 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 40 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Sharon Wang-Price | ClinicalTrials.gov |
| Conditions | Chronic Low Back Pain | ClinicalTrials.gov |
| Interventions | Active music-based intervention | ClinicalTrials.gov |
| First posted | 2025-04-23 | ClinicalTrials.gov |
| Last updated | 2026-01-09 | ClinicalTrials.gov |
Registered outcomes 5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Cognitive function | This outcome measure (SCWT) will be administered twice, before the start of treatment and after the end of treatment at 2 weeks. | Cognitive function will be assessed using the Stroop Color and Word Test (SCWT). The SCWT is used to measure a person's attentional interference or the ability to inhibit the interference of a second stimulus while continuing to process an original stimulus. A computerized version of the SCWT via a software program DirectRT (Empirisoft Corp., New York, NY) will be used. The SCWT consists of 3 parts, each containing 24 consecutive stimuli. A reaction time will be computed in software based on the speed of the participant's response. | ClinicalTrials.gov |
| Primary | Cognitive function | This outcome measure (CTMT2) will be administered twice, before the start of treatment and after the end of treatment at 2 weeks. | Cognitive function will be assessed using the Comprehensive Trail Making Test - Second Edition (CTMT2). The CTMT2 consists of 5 trails requiring cognitive control between competing stimuli and schemas. Trails 1-3 measure inhibitory control by completing trails with increasing numbers of distractors. Trails 4-5 measure set-shifting by requiring participants to shift between opposing mental sets (i.e., numbers and letters). The test will use standardized instructions. | ClinicalTrials.gov |
| Secondary | Sensitivity to stimuli | This outcome measure (PPT) will be administered twice, before the start of treatment and after the end of treatment at 2 weeks. | Pressure pain threshold (PPT) will be used to determine the level of sensitivity to stimuli using a hand-held computerized pressure algometer (Medoc ltd., Ramat Yishai, Israel). The algometer will be pressed vertically on the most tender point of the participant's low back. To provoke the participant's pain or discomfort, pressure will be increased at a rate of 40 kPa/sec until the participant feels pain as indicated by pressing the patient safety button. Three trials of PPT testing will be administered. | ClinicalTrials.gov |
| Secondary | Pain catastrophizing | This outcome measure (PCS) will be administered twice, before the start of treatment and after the end of treatment at 2 weeks. | Pain catastrophizing will be assessed using the Pain Catastrophizing Scale (PCS). The PCS is a 13-item questionnaire that requires the participants to select their level of agreement for each item on a 5-point Likert scale. The total score ranges from 0-52, with a higher score indicating greater levels of pain catastrophizing | ClinicalTrials.gov |
| Secondary | Health-related Quality of life | This outcome measure (PROMIS-29) will be administered twice, before the start of treatment and after the end of treatment at 2 weeks. | Health-related quality of life will be determined by the Patient-Reported Outcomes Measurement Information System -29 (PROMIS-29). The PROMIS-29 is a 29-item questionnaire that assesses general health-related quality of life across 7 domains (i.e., physical function, pain interference, anxiety, depression, fatigue, sleep disturbance, and social roles) and pain intensity. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 3
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Trail Making Test A | Primary outcome | ConductCognition |
| Trail Making Test B | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)